Additional Relevant Details abstracts from its Hepatitis Delta Virus (HDV) development program will be presented at the European Association for the Study of the Liver (EASL) meeting in Barcelona, Spain, April 13 to 17, 2016.  In addition, interim data from the LOWR HDV – 2 (LOnafarnib With Ritonavir in Hepatitis Delta Virus – 2) Phase 2 study in patients infected with HDV will be presented for the first time at the Hepatitis Delta International Network meeting (HDIN) at EASL.LOWR HDV – 2 is a dose finding study to identify optimal combination regimens of lonafarnib (LNF) and ritonavir (RTV) ± PEG-IFN-α, with efficacy and tolerability for longer term dosing to enable HDV RNA clearance. In this study, approximately 40 HDV infected patients have been enrolled to date into 9 groups of different doses of LNF in combination with RTV for dosing durations of 12 or 24 weeks. LNF doses range from 150 mg qd to 25 mg bid.  Quantitative serum HDV RNA viral loads, biochemical parameters, and lonafarnib drug levels were measured. As of March 2016, over 30 patients have received at least 12 weeks of treatment in LOWR HDV-2.